Developer docs
API playgroundTry for free, no card

Search company profiles

Atrium Therapeutics

Full company profile

uuid00q3cfi

Namestring
Atrium Therapeutics
Legal namestring
Atrium Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2026
Descriptiontext

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision RNA medicines for rare genetic cardiomyopathies. The company was established February 27, 2026 as an independent publicly traded entity on Nasdaq (ticker: RNA), spun off from Avidity Biosciences following Novartis AG's approximately $12 billion acquisition of Avidity. Atrium launched with approximately $270 million in cash and acquired the proprietary AOC (Antibody-Oligonucleotide Conjugate) RNA delivery platform originally designed at Avidity, which combines monoclonal antibody tissue selectivity with oligonucleotide precision to enable targeted, non-viral siRNA delivery to cardiac tissue, circumventing cytotoxicity, immunogenicity, and redosing limitations that constrain alternative delivery systems.

The company's pipeline is anchored by two lead siRNA candidates: ATR 1072 for PRKAG2 syndrome (IND filing planned H2 2026) and ATR 1086 for PLN cardiomyopathy (IND filing planned 2027), with two additional undisclosed research-stage targets in rare cardiomyopathies. The patient population targeted is small but underserved — approximately 1,000-2,000 US patients for PRKAG2 syndrome and 2,000-4,000 US patients for PLN cardiomyopathy, with no approved disease-modifying therapies currently addressing the underlying genetic drivers of either condition. Atrium's headquarters is in San Diego, California, and the company operates with 11-50 employees under a leadership team and board composed primarily of former Avidity Biosciences executives.

Atrium's business model is anchored by a global licensing and research collaboration with Bristol Myers Squibb (announced April 23, 2026) covering discovery, development, and commercialization of RNA-based cardiovascular therapies. BMS funds all future clinical development, regulatory, and commercialization activities, and Atrium is eligible for up to approximately $1.35 billion in R&D milestones, up to $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales. Q1 2026 collaboration revenue was $19.6 million, primarily a $15 million BMS milestone payment plus R&D services revenue. As a pre-commercial biotech, Atrium does not yet sell any approved products and depends on milestone payments, R&D services fees, and eventual royalties as its revenue streams.

Short descriptiontext

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision siRNA medicines using its proprietary AOC delivery platform to target rare genetic cardiomyopathies (PRKAG2 syndrome and PLN cardiomyopathy), operating primarily through a global licensing and research collaboration with Bristol Myers Squibb.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA therapeutics, cardiac RNA delivery, siRNA drug development, rare cardiomyopathy treatments, antibody-oligonucleotide conjugates
Industry3 codes
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision RNA Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration/Partnership Revenue
TypeLicensing Royalties
Description

Atrium earns milestone payments and royalties through its global licensing and research collaboration with Bristol Myers Squibb for RNA-based cardiovascular therapies. The company is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales.

investors.atriumtherapeutics.com
2R&D Services Revenue
TypeProfessional Services
Description

Revenue generated from research and development services provided under collaboration agreements, including delivery of development candidates. Q1 2026 included $19.6 million in collaboration revenue, with $15 million from BMS milestone payment and remainder from R&D services.

investors.atriumtherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision RNA therapeutics for rare genetic cardiomyopathies using its proprietary antibody-oligonucleotide conjugate (AOC) delivery platform. Its lead pipeline candidates are ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both siRNA therapies designed to address the underlying genetic drivers of these life-threatening cardiac conditions. The company partnered with Bristol Myers Squibb for global clinical development and commercialization under a deal worth up to approximately $2.175 billion in milestones plus royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Up to approximately $1.35 billion in R&D milestone payments plus up to $825 million in commercial milestone payments plus tiered royalties up to low double-digits on net sales from BMS collaboration
+1 more record
Product overview1 text field

Atrium Therapeutics is a biopharmaceutical company pioneering targeted delivery of RNA therapeutics to the heart for precision cardiology. The company operates a platform-plus-pipeline model, with its proprietary AOC (antibody-oligonucleotide conjugate) RNA delivery platform as the core technology enabling the development of multiple therapeutic candidates. The lead pipeline candidates are ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both siRNA-based therapies targeting the underlying genetic drivers of rare cardiomyopathies. The company also has two undisclosed research-stage targets in rare cardiomyopathies.

Product and service2 records
1ATR 1072
CategoryCore drug candidate
Description

siRNA therapeutic candidate for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome that works through sequence-specific gene silencing to reduce PRKAG2 mRNA, normalize AMPK activity, and reduce pathogenic glycogen accumulation in cardiac muscle cells, with the goal of improving heart function in patients with this rare genetic cardiomyopathy.

2ATR 1086
CategoryCore drug candidate
Description

Therapeutic candidate for PLN (phospholamban) cardiomyopathy designed to address the underlying genetic driver of disease by reducing PLN expression in cardiac muscle, relieving SERCA2a inhibition, and restoring calcium cycling dynamics.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-23
Description

Global licensing and research collaboration focused on discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications. Atrium is eligible to receive up to approximately $1.35 billion in R&D milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from the collaboration. The milestone payment of $15 million was achieved upon successful delivery of a development candidate for the first licensed compound targeting a cardiology indication.

investors.atriumtherapeutics.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-27
Description

Spin-off relationship from Novartis AG's acquisition of Avidity Biosciences. Atrium acquired the targeted RNA delivery platform (AOC technology) originally designed at Avidity, along with early-stage precision cardiology programs (ATR 1072 and ATR 1086) and approximately $270 million in cash. The proprietary AOC technology combines the tissue selectivity of monoclonal antibodies and other targeted delivery ligands with the precision of oligonucleotides for targeted siRNA delivery to cardiac tissues.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Original developer of the AOC platform that Atrium was built around and spun out from. Directly comparable RNA therapeutics platform company with antibody-oligonucleotide conjugate technology targeting muscle and other tissues; recently acquired by Novartis for ~$12B.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company focused on rare genetic diseases using stereopure oligonucleotide platform. Comparable modality (oligonucleotide-based) and similar pipeline-stage economics, though with different delivery technology.

TypeDirect peer
Description

Leading RNA-targeted therapeutics company and parent lineage of Atrium's COO and several board members (Akcea). Pioneered antisense oligonucleotide technology and many rare disease programs; a direct comparable given similar RNA modality focus and rare disease commercialization expertise.

TypeDirect peer
Description

Cardiology-focused specialty biotech developing cardiac myosin modulators for HCM and other cardiomyopathies. Directly comparable target patient population (HCM, PLN/RBM20 carriers) and overlapping cardiology pipeline ambition.

TypeDirect peer
Description

Genetic cardiomyopathy-focused biotech developing AAV gene therapies for HCM, DCM and other rare cardiac indications. Directly comparable precision-cardiology strategy targeting genetic drivers of cardiomyopathies using a different modality (gene therapy).

TypeEmerging player
Description

Cardiology gene therapy biotech with programs targeting cardiomyopathies including PLN-related disease. Comparable genetic cardiology focus and parallel therapeutic pursuit of PLN cardiomyopathy, providing a competitive cross-reference.

TypeDirect peer
Description

Established siRNA therapeutics leader with approved RNAi drugs (Onpattro, Givlaari, Oxlumo, Amvuttra). Directly comparable RNA modality platform serving rare and cardiometabolic indications; defines the commercial RNA therapeutics benchmark.

TypeBroad incumbent
Description

Broader rare genetic disease drug developer with cardiovascular programs including attruby (acoramidis) for ATTR-CM. Comparable genetic cardiology/rare disease focus and similar partnership-driven development model.

TypeEmerging player
Description

Cardiovascular-focused clinical-stage biotech developing kinase and PDE inhibitors for heart failure and rare cardiomyopathies. Comparable focus on genetic and rare cardiac disease drug development though small-molecule modality.

TypeDirect peer
Description

Clinical-stage RNAi therapeutics company with proprietary siRNA delivery technology and broad pipeline including cardiovascular programs. Comparable RNAi platform approach and cardiac indication ambition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atrium Therapeutics

Precision RNA Therapeuticsatriumtherapeutics.com

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision siRNA medicines using its proprietary AOC delivery platform to target rare genetic cardiomyopathies (PRKAG2 syndrome and PLN cardiomyopathy), operating primarily through a global licensing and research collaboration with Bristol Myers Squibb.

What Atrium Therapeutics does

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision RNA medicines for rare genetic cardiomyopathies. The company was established February 27, 2026 as an independent publicly traded entity on Nasdaq (ticker: RNA), spun off from Avidity Biosciences following Novartis AG's approximately $12 billion acquisition of Avidity. Atrium launched with approximately $270 million in cash and acquired the proprietary AOC (Antibody-Oligonucleotide Conjugate) RNA delivery platform originally designed at Avidity, which combines monoclonal antibody tissue selectivity with oligonucleotide precision to enable targeted, non-viral siRNA delivery to cardiac tissue, circumventing cytotoxicity, immunogenicity, and redosing limitations that constrain alternative delivery systems.

The company's pipeline is anchored by two lead siRNA candidates: ATR 1072 for PRKAG2 syndrome (IND filing planned H2 2026) and ATR 1086 for PLN cardiomyopathy (IND filing planned 2027), with two additional undisclosed research-stage targets in rare cardiomyopathies. The patient population targeted is small but underserved — approximately 1,000-2,000 US patients for PRKAG2 syndrome and 2,000-4,000 US patients for PLN cardiomyopathy, with no approved disease-modifying therapies currently addressing the underlying genetic drivers of either condition. Atrium's headquarters is in San Diego, California, and the company operates with 11-50 employees under a leadership team and board composed primarily of former Avidity Biosciences executives.

Atrium's business model is anchored by a global licensing and research collaboration with Bristol Myers Squibb (announced April 23, 2026) covering discovery, development, and commercialization of RNA-based cardiovascular therapies. BMS funds all future clinical development, regulatory, and commercialization activities, and Atrium is eligible for up to approximately $1.35 billion in R&D milestones, up to $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales. Q1 2026 collaboration revenue was $19.6 million, primarily a $15 million BMS milestone payment plus R&D services revenue. As a pre-commercial biotech, Atrium does not yet sell any approved products and depends on milestone payments, R&D services fees, and eventual royalties as its revenue streams.

Atrium Therapeutics firmographics

Firmographics
Name
Atrium Therapeutics
Legal name
Atrium Therapeutics, Inc.
Website
https://atriumtherapeutics.com
Company type
Public
Founded year
2026
Operating status
Operating
Headcount range
51–100 employees
Short description
Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision siRNA medicines using its proprietary AOC delivery platform to target rare genetic cardiomyopathies (PRKAG2 syndrome and PLN cardiomyopathy), operating primarily through a global licensing and research collaboration with Bristol Myers Squibb.
Ownership category
akta.pro rank

Atrium Therapeutics industry classification

Industry
Product category
Precision RNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • RNA therapeutics
  • Cardiac RNA delivery
  • SiRNA drug development
  • Rare cardiomyopathy treatments
  • Antibody-oligonucleotide conjugates

Where Atrium Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Atrium Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Collaboration/Partnership Revenue: Atrium earns milestone payments and royalties through its global licensing and research collaboration with Bristol Myers Squibb for RNA-based cardiovascular therapies. The company is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales.
  2. R&D Services Revenue: Revenue generated from research and development services provided under collaboration agreements, including delivery of development candidates. Q1 2026 included $19.6 million in collaboration revenue, with $15 million from BMS milestone payment and remainder from R&D services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Atrium Therapeutics product offering

Product offering

Core offering

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision RNA therapeutics for rare genetic cardiomyopathies using its proprietary antibody-oligonucleotide conjugate (AOC) delivery platform. Its lead pipeline candidates are ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both siRNA therapies designed to address the underlying genetic drivers of these life-threatening cardiac conditions. The company partnered with Bristol Myers Squibb for global clinical development and commercialization under a deal worth up to approximately $2.175 billion in milestones plus royalties.

Product overview

Atrium Therapeutics is a biopharmaceutical company pioneering targeted delivery of RNA therapeutics to the heart for precision cardiology. The company operates a platform-plus-pipeline model, with its proprietary AOC (antibody-oligonucleotide conjugate) RNA delivery platform as the core technology enabling the development of multiple therapeutic candidates. The lead pipeline candidates are ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both siRNA-based therapies targeting the underlying genetic drivers of rare cardiomyopathies. The company also has two undisclosed research-stage targets in rare cardiomyopathies.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATR 1072 siRNA therapeutic candidate for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome that works through sequence-specific gene silencing to reduce PRKAG2 mRNA, normalize AMPK activity, and reduce pathogenic glycogen accumulation in cardiac muscle cells, with the goal of improving heart function in patients with this rare genetic cardiomyopathy.
  • ATR 1086 Therapeutic candidate for PLN (phospholamban) cardiomyopathy designed to address the underlying genetic driver of disease by reducing PLN expression in cardiac muscle, relieving SERCA2a inhibition, and restoring calcium cycling dynamics.

Quantifiable outcome

  • Up to approximately $1.35 billion in R&D milestone payments plus up to $825 million in commercial milestone payments plus tiered royalties up to low double-digits on net sales from BMS collaboration
  • +1 more outcomes

Companies that use Atrium Therapeutics

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Atrium Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Atrium Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 23 April 2026Global licensing and research collaboration focused on discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications. Atrium is eligible to receive up to approximately $1.35 billion in R&D milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. Bristol Myers Squibb will fund all future clinical development, regulatory and commercialization activities coming from the collaboration. The milestone payment of $15 million was achieved upon successful delivery of a development candidate for the first licensed compound targeting a cardiology indication.
  • Avidity BiosciencescoreTechnology or Integration · 27 February 2026Spin-off relationship from Novartis AG's acquisition of Avidity Biosciences. Atrium acquired the targeted RNA delivery platform (AOC technology) originally designed at Avidity, along with early-stage precision cardiology programs (ATR 1072 and ATR 1086) and approximately $270 million in cash. The proprietary AOC technology combines the tissue selectivity of monoclonal antibodies and other targeted delivery ligands with the precision of oligonucleotides for targeted siRNA delivery to cardiac tissues.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Atrium Therapeutics competitors and assessment

Company assessment

Direct peers

  • Avidity Biosciences: Original developer of the AOC platform that Atrium was built around and spun out from. Directly comparable RNA therapeutics platform company with antibody-oligonucleotide conjugate technology targeting muscle and other tissues; recently acquired by Novartis for ~$12B.
  • Wave Life Sciences: Clinical-stage RNA therapeutics company focused on rare genetic diseases using stereopure oligonucleotide platform. Comparable modality (oligonucleotide-based) and similar pipeline-stage economics, though with different delivery technology.
  • Ionis Pharmaceuticals: Leading RNA-targeted therapeutics company and parent lineage of Atrium's COO and several board members (Akcea). Pioneered antisense oligonucleotide technology and many rare disease programs; a direct comparable given similar RNA modality focus and rare disease commercialization expertise.
  • Cytokinetics: Cardiology-focused specialty biotech developing cardiac myosin modulators for HCM and other cardiomyopathies. Directly comparable target patient population (HCM, PLN/RBM20 carriers) and overlapping cardiology pipeline ambition.
  • Tenaya Therapeutics: Genetic cardiomyopathy-focused biotech developing AAV gene therapies for HCM, DCM and other rare cardiac indications. Directly comparable precision-cardiology strategy targeting genetic drivers of cardiomyopathies using a different modality (gene therapy).
  • Alnylam Pharmaceuticals: Established siRNA therapeutics leader with approved RNAi drugs (Onpattro, Givlaari, Oxlumo, Amvuttra). Directly comparable RNA modality platform serving rare and cardiometabolic indications; defines the commercial RNA therapeutics benchmark.
  • Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with proprietary siRNA delivery technology and broad pipeline including cardiovascular programs. Comparable RNAi platform approach and cardiac indication ambition.

Emerging players

  • Lexeo Therapeutics: Cardiology gene therapy biotech with programs targeting cardiomyopathies including PLN-related disease. Comparable genetic cardiology focus and parallel therapeutic pursuit of PLN cardiomyopathy, providing a competitive cross-reference.
  • Cardurion Pharmaceuticals: Cardiovascular-focused clinical-stage biotech developing kinase and PDE inhibitors for heart failure and rare cardiomyopathies. Comparable focus on genetic and rare cardiac disease drug development though small-molecule modality.

Broad incumbents

  • BridgeBio Pharma: Broader rare genetic disease drug developer with cardiovascular programs including attruby (acoramidis) for ATTR-CM. Comparable genetic cardiology/rare disease focus and similar partnership-driven development model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Atrium Therapeutics social profiles

Digital presence

Atrium Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atrium Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Atrium Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atrium Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atrium Therapeutics

What does Atrium Therapeutics do?

Atrium Therapeutics is a clinical-stage biopharmaceutical company developing precision RNA therapeutics for rare genetic cardiomyopathies using its proprietary antibody-oligonucleotide conjugate (AOC) delivery platform. Its lead pipeline candidates are ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both siRNA therapies designed to address the underlying genetic drivers of these life-threatening cardiac conditions. The company partnered with Bristol Myers Squibb for global clinical development and commercialization under a deal worth up to approximately $2.175 billion in milestones plus royalties.

Is Atrium Therapeutics a public or private company?

Atrium Therapeutics is a public company. It is classified as public and is currently operating.

When was Atrium Therapeutics founded?

Atrium Therapeutics was founded in 2026. It employs 51 to 100 people.

Where is Atrium Therapeutics based?

Atrium Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Atrium Therapeutics make money?

Two revenue lines are on record. Collaboration/Partnership Revenue is the primary driver. The others are R&D Services Revenue.

Who are Atrium Therapeutics's main competitors?

Direct peers on record are Avidity Biosciences, Wave Life Sciences, Ionis Pharmaceuticals, Cytokinetics, Tenaya Therapeutics, Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals. Emerging players are Lexeo Therapeutics and Cardurion Pharmaceuticals. BridgeBio Pharma is listed as a broad incumbent.

Does Atrium Therapeutics have an API?

No public API is recorded for Atrium Therapeutics.

What industry is Atrium Therapeutics in?

Atrium Therapeutics's product category is Precision RNA Therapeutics. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanAtrium Therapeutics Q3 earnings: $293.6M pro forma cashAtrium Therapeutics reported Q3 2026 results, including $15.3M collaboration revenue and $13.8M R&D expenses. The company's pro forma cash balance was $293.6M, extending its runway through 2028. It also dosed the first patient in the Corventis Phase 1/2 trial of ATR 1072 for PRKAG2 syndrome.PR NewswireAtrium Therapeutics Reports Third Quarter 2026 Financial ResultsAtrium Therapeutics reported Q3 2026 results, including first patient dosed in the Corventis Phase 1/2 trial of ATR 1072 for PRKAG2 syndrome. The company closed a $50 million private placement, extending its cash runway through 2028, and expects initial proof-of-concept data from Corventis in the second half of 2027.Investing.comAtrium Therapeutics at stifel 2026 healthcare conference: cash, pipelineAtrium Therapeutics presented its precision RNA platform for cardiac disease at the Stifel 2026 Healthcare Conference, citing strong financing and early clinical momentum. The company has cash through 2028, with its lead program ATR-1072 in the Corventis trial for PRKAG2 syndrome, and expects proof-of-concept data in the second half of 2027.TradingViewHC Wainwright & Co. maintains Buy rating on Atrium Therapeutics, $20 price targetHC Wainwright & Co. maintained a Buy rating on Atrium Therapeutics with a $20 price target, implying 140.4% upside from the Oct 27 close of $8.32. The rating cites promising clinical progress, including the Corventis study for ATR 1072, and a $50 million financing that extends cash runway to 2028.The future of tradingAtrium Therapeutics Presents Preclinical Data Showing ATR1072 Normalizes Key Cardiac Function MeasuresAtrium Therapeutics presented preclinical data showing ATR1072 improved cardiac relaxation and atrial signaling in a nine-month monkey study. The company also identified nearly 2,000 individuals with PRKAG2 mutations, suggesting the syndrome's prevalence exceeds the initial estimate of 1,000-2,000 patients.Investing.comRoth/MKM initiates Atrium Therapeutics stock with buy ratingRoth/MKM initiated coverage on Atrium Therapeutics with a Buy rating and a $15 price target. The firm sees the company as a focused cardiac-RNA franchise targeting rare cardiomyopathies, with a pipeline including ATR1072 for PRKAG2 syndrome and ATR1086 for PLN cardiomyopathy. The stock trades near its 52-week low, and Cantor Fitzgerald has reiterated an Overweight rating.TradingViewYakira Capital Management, Inc. Urges Atrium to Launch Strategic Review, Questioning $50M RaiseYakira Capital Management, a shareholder of Atrium Therapeutics, publicly urged the board to launch a strategic review and cut spending. It questioned the company's ~$50M private placement at ~$7.93 per share after a ~44% stock drop, citing an estimated net cash of ~$254M.TradingViewYakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingYakira Capital Management urged Atrium Therapeutics' board to launch a strategic review and curb spending after the company raised $50 million in a private placement at a depressed valuation. The financing follows a ~44% share drop and leaves shareholders facing dilution, with Yakira citing net cash and collaboration value as undervalued.Stock TitanYakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingYakira Capital Management urged Atrium Therapeutics' board to launch a strategic review and curb spending after the company raised $50 million in a private placement at a depressed valuation. The financing follows a ~44% stock drop and leaves shareholders facing dilution, with Yakira questioning whether alternatives like a rights offering were considered.Investing.comCantor Fitzgerald reiterates Atrium Therapeutics stock OverweightCantor Fitzgerald reiterated an Overweight rating and $25 price target on Atrium Therapeutics, updating its model after a $50 million private placement. The financing extends cash runway to 2028, and the firm expects the market to recognize the company's undervaluation ahead of the first clinical readout next year.